Co-Authors
This is a "connection" page, showing publications co-authored by PATRICK CHAFTARI and ANNE-MARIE P CHAFTARI.
Connection Strength
1.943
-
A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. J Antimicrob Chemother. 2024 Oct 01; 79(10):2543-2553.
Score: 0.248
-
International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. Elife. 2023 01 30; 12.
Score: 0.221
-
International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship. medRxiv. 2022 Aug 26.
Score: 0.215
-
A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies. Open Forum Infect Dis. 2022 Jun; 9(6):ofac079.
Score: 0.207
-
The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score. Cancer Med. 2021 12; 10(23):8475-8482.
Score: 0.203
-
Prognostic Value of Procalcitonin, C-Reactive Protein, and Lactate Levels in Emergency Evaluation of Cancer Patients with Suspected Infection. Cancers (Basel). 2021 Aug 13; 13(16).
Score: 0.200
-
Unnecessary Removal of Central Venous Catheters in Cancer Patients with Bloodstream Infections. Infect Control Hosp Epidemiol. 2018 02; 39(2):222-225.
Score: 0.156
-
Improvement in the diagnosis of catheter-related bloodstream infections in a tertiary cancer center. Am J Infect Control. 2017 Mar 01; 45(3):e34-e39.
Score: 0.147
-
Procalcitonin Level Monitoring in Antibiotic De-Escalation and Stewardship Program for Patients with Cancer and Febrile Neutropenia. Cancers (Basel). 2024 Oct 11; 16(20).
Score: 0.062
-
Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients. Cancers (Basel). 2024 Mar 05; 16(5).
Score: 0.060
-
Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. Elife. 2023 02 07; 12.
Score: 0.055
-
Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clin Infect Dis. 2021 11 02; 73(9):e2697-e2704.
Score: 0.051
-
Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer. Clin Infect Dis. 2018 08 31; 67(6):971-977.
Score: 0.041
-
Author Correction: Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia. Sci Rep. 2018 Apr 19; 8(1):6258.
Score: 0.040
-
Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia. Sci Rep. 2018 01 18; 8(1):1099.
Score: 0.039